Recursion
RXRX
Performance
About Recursion
Recursion is a biotechnology company leveraging AI-driven drug discovery to decode biology and accelerate the development of new medicines. By imaging cells and training machine learning models on phenomics, transcriptomics, and other omics data, they aim to shorten hit identification to IND-enabling studies and improve success rates in areas like oncology and rare diseases. The company operates from Salt Lake City, Utah, and emphasizes its Recursion Operating System and partnerships with pharma and tech leaders to advance faster, cost-efficient drug development.
Recent News
The 5 Largest IPOs in Biopharma History
AI Needs a Reality Check
Ship Fast, Optimize Later: Top AI Engineers Don't Care About Cost — They're Prioritizing Deployment
Ovid Takes Another Big Swing in Neuroscience Under a New CEO
What’s Next for AlphaFold: A Conversation with a Google DeepMind Nobel Laureate
Alamar Biosciences Upsizes IPO, Raises $191.3 M to Accelerate Cell‑Based Drug Discovery
Theorem Wants to Stop AI-Written Bugs Before They Ship — and Just Raised $6M to Do It
Goldman Is Betting Nvidia Will Get a Boost From Health Care as Industry Builds Out AI Capabilities
Biotech Has Become a Good News Story. Let the Sun Shine
Takeda, Iambic Partner in Latest Pharma AI Push
Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline Partnership
Recent Deals
No recent deals for this company.